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Abstract
Analgesics, the cornerstone for the alleviation of both acute and chronic pain, represent
one of the most used classes of medications. While they are essential for the improve-
ment of patients’ quality of life, analgesic use is often associated with adverse drug
reactions (ADRs) that might affect their usability in particular clinical situations. This
indicates that a detailed knowledge of analgesic-derived ADRs is essential for the
planning of an efficient pain relief strategy. This chapter reviews the ADRs associated
with the two most commonly used analgesic classes, opioid and nonsteroidal anti-
inflammatory drugs (NSAID), discussing their common adverse effects and how these
can influence their usability in clinical applications. With the publication in recent years
of more and more long-term studies, this chapter also provides an overview of the
potential risks of long-term analgesic use. This is particularly important for opioid
analgesics, whose chronic use can lead to analgesic tolerance and addiction. A full
description of potential problems deriving from analgesic use represents the first step
in optimizing protocols for its safe application in clinical settings.
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1. Introduction
Pain relief, both for acute and chronic pain, is an important aspect of modern medicine and
healthcare services [1]. Pain is defined as ‘an unpleasant sensory and emotional experience
associated with actual or potential tissue damage, or described in terms of such damage’ by the
International Association for the Study of Pain (IASP) [2]: as such, it strongly worsens the
quality of life of patients and remains one of the most common reasons for using health care
services [1]. Pain relief drugs in the form of analgesics represent one of the most commonly
used medications. While analgesics may include different therapeutic active compounds,
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covering specific pain relief needs, opioid medications and nonsteroidal anti-inflammatory
drugs (NSAIDs) remain the most commonly used analgesics [1, 3, 4].
Pain relief management teams have to be aware of the exact nature of the pain itself and its
intensity, and must be able to differentiate between acute and chronic pain. These are not only
essential factors for pain management itself, but this could also lead to the consideration of
possible adverse drug reactions (ADRs) from analgesic use. Indeed, when implementing pain
relief management, one must consider the best practice to alleviate pain directly, along with the
possibility of having ADRs which would then defeat the purpose of analgesics use itself [5–8].
Additionally, chronic pain is associated with an increased incidence of mental health issues
such as anxiety and depression [9]; thus, there is a need to extend the consequences of
inefficient pain relief beyond pain management alone.
The proper use of analgesics, that is, targeted drug use against specific types of pain, can
avoid or at least minimize ADRs. In this regard, scientific studies reporting on ADRs caused
by analgesics become an invaluable tool to predict and prevent ADRs and to evaluate the
safety of analgesics in different pain relief practices. While short-term side effects are gener-
ally easier to observe, long-term effects, particularly in chronic analgesic users, need spe-
cially designed studies or a careful review of previous literature. In the last few years, more
literature has been made available that addresses ADRs of both the opioid and NSAID type,
allowing for the re-evaluation of the safety of these two medication classes, including their
chronic long term use [10–16].
In order to draw attention to analgesic an their risks and to minimize the negative conse-
quences related to their use, the present review comprises a synthesis of the most important
safety issues described in scientific literature. This stands as a broad overview of the topic,
providing a basic understanding of safety issues associated with analgesics and a starting
point for further understanding of the subject at hand.
The ADRs associated with the two most commonly used analgesic classes, opioid and nonste-
roidal anti-inflammatory drugs (NSAID), discussing their common adverse effects and how
these can influence their usability in clinical applications. In recent years, more and more long-
term studies have been published providing an insight into the potential risks of long-term
analgesic use, this chapter provides a thorough overview. This is particularly important when
discussing opioid analgesics, whose chronic use can lead to analgesic tolerance and even
addiction. A full description of the potential problems derived from analgesic use represents
the first step in optimizing protocols for its safe application in clinical settings.
2. Opioids
The use of opioids has significantly increased during the last decade and concomitantly the
occurrence of related ADRs has become more frequent [3, 17]. Opioids are, by definition,
ligands for opioid neuroreceptors, thereby modulating them and their associated responses
[3]. With opioid receptors controlling a variety of physiological processes, exogenous opioid
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application results, therefore, in an imbalance in receptor activity and a potential plethora of
side effects.
Sedation is a common short-term ADR because of the anticholinergic effect of opioids. Drows-
iness, sedation, nausea and vomiting could all be seen after treatment with opioids, and
usually occurs in dosage transition states. Sedation represents the best early clinical indicator
of respiratory depression [18]. A number of blind studies confirm this effect which seems
particularly evident for methylphenidate [19–21].
On the other side of the spectrum, opioids also appear to disturb the normal sleep cycles. This
is likely due to the interference of this class of molecules with the action or binding of sleep-
related neurotransmitters, such as noradrenaline, serotonin, acetyl choline, dopamine, hista-
mine and gamma-aminobutyric acid [22]. Although this effect appears to be limited to the
depth of sleep and duration of the REM (Rapid eye movement) phase rather than the quality of
sleep itself [23, 24], this factor might be worth considering when opioid treatments worsen
sleep disturbances derived from an underlying condition.
Constipation is also a common side effect reported in opioid users, due to the activation of mu
receptors and the consequent modulation of gut motility [25]. Opioid-induced constipation is
very diffused, with a single opioid treatment alone being able to induce constipation [26], this
condition does not improve over time, and so its management should be planned in advance
before the start of an opioid regimen. In recent studies, the naloxone-oxycodone combination
has been shown to reduce constipation [25, 26], which favours an improved quality of life for
patients.
Long-term use of opioids may also lead to additional complications, for example a hormonal
imbalance [27, 28]. These ADRs are well known in the medical arena, to the point where the
terms opioid endocrinopathy (OE) and opioid-induced androgen deficiency (OPIAD) both
appear in the literature. Opioid users often display an imbalance in estrogen, testosterone,
adrenocorticotropin, cortisol, and corticotropin-releasing hormone, luteinizing hormone,
gonadotrophin-releasing hormone, dehydroepiandrosterone and dehydroepiandrosterone
sulphates. This accounts for the increase reports of depression and sexual dysfunction among
both sexes, while women are also at risk of a potential loss in bone mineral density [27, 28].
A well-known complication of opioid use is the potential development of physical addic-
tion and opioid tolerance [29]. Both short- and long-term opioid use can induce these
problems and due to the fact that they particularly affect chronic pain patients, incorrect
use of opioids in this group of users could become both dangerous and ineffective.
Opioid tolerance is dependent on both the patient and the specific opioid employed [30]. This
means that tolerance developed for a specific opioid does not automatically affect the efficacy
of another opioid medication. However, in conjunction with the risk of hyperalgesia [31],
which is, an increase in pain sensitivity also present in opioid users, this might still lead to an
abuse of prescription medication, a particularly sensitive topic in opioid research.
Pruritus is another common adverse effect of opioids, more frequent with the parenteral route
than oral. Opioid-induced pruritus is primarily mediated by mu-opioid receptors, serotonin
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receptors and to a lesser extent by histamine. The first-line treatment for pruritus should
include low-dose nalbuphine, low-dose naloxone and ondansetron; antihistamines are less
efficient. In addition to these common side effects, there are also ADRs for specific opioids.
The most common ones are summarized in Table 1.
To further reduce the ADRs caused by opioid administration, several measures have been
suggested in the form of guidelines to ensure that an effort is being made on the part of the
health care providers to reduce the amount of ADRs that occur with opioid drug administration.
The health care provider must ensure that before prescribing opioids to a patient, one has
thoroughly documented the patient's diagnosis, medical well-being at the time and more
importantly their psychological, psychiatric and social state, including whether or not the
patient has abused any drugs in the past.
A patient who is now presenting with a pain condition should be asked questions regarding
any previous medical or surgical treatments that may have been performed, along with
clarifying and quantifying the present intensity of pain and how this may be affecting their
daily activities of living.
Along with the patient's present physical state of health, a health care provider would also find
it beneficial to inquire on the patient's living conditions, whether or not the patient has easy
access to family and/or social support, and if the patient currently has a job or any domestic
duties.
The psychiatric status of the patient is especially important. Knowing whether or not there
has been a diagnosis of any psychiatric disorders in the past and how they were treated can
greatly reduce the chances of the related ADRs or opioid addiction; some guidelines sug-
gest to initiate with a low opioid dose and monitor the patient daily [32] when dealing with
a patient who has a co-morbid psychiatric condition or a family history of psychiatric
disorders.
Gastrointestinal Constipation
Nausea
Vomiting
Cutaneous Pruritus
Sweating
Neurologic Sedation/fatigue
Headache
Delirium/confusion
Clouded vision
Dizziness
Autonomic Xerostomia
Bladder dysfunction (e.g. urinary retention)
Postural hypotension
Table 1. Most commonly reported opioid-induced side effects [3].
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Furthermore, substance use history is vital to formulate a comprehensive knowledge of the
patient. A physician should inquire on the patient's history of substance use, abuse and
addiction, namely marijuana, tobacco, benzodiazepines, opioids themselves, cocaine, amphet-
amines, barbiturates, hallucinogens and solvents.
After gathering all the information necessary to formulate a management plan, the physician
should use this information to perform risk screening for the patient, assessing the potential for
opioid drug misuse, overdose and addiction, looking at aberrant drug-related behaviours and
if necessary, employing a urine drug screening.
Patients and their health care providers should then initiate goal setting in order to find out
what the patient's goals are and how feasible the treatment could be, along with fully
documenting what specific goals have been agreed on by the patient with the health care
provider.
Additionally, documented informed consent for the use of opioids is suggesting, enabling the
doctor and patient to explore the benefits, adverse effects. Medical complications and risks that
may be encountered during the course of opioid treatment should also be determined and
discussed with the patient, especially with high risk groups including the elderly, adolescent,
pregnant, breastfeeding and those with co-morbid psychiatric conditions and those on long-
term opioid treatment.
Moreover, one should verify and confirm that they have selected the most appropriate opioid
for treatment of their patients, this should be done using peer-reviewed evidence which
specifies which drug and what dose is used for first, second and third line treatment for the
specific pain condition that the patient has.
After reviewing current data on the topic and starting a treatment regimen, one should
continuously monitor the dose of opioid being given. If the patient is taking a dose on the
higher end of the scale, the health care provider should re-asses the patient's pain condition to
note if the medication is effective at reducing the pain (at least 30% reduction), and are there
any non-opioid treatment options available.
Also, the doctor should clarify that all mental health disorders are adequately treated, that any
ADRs are being managed and lastly if there is any sign of abnormal drug-related behaviours,
the physician should then taper or switch the medication appropriately. After all these precau-
tionary measures are taken, one should remember that arranging a consultation with an expert
in pain or addiction management is always an option that could only benefit the patient
greatly [33].
Health care providers should also consider alternative recommendations to replace long-
term opioid treatment. Over the counter alternatives include acetaminophen and low dose
NSAIDS. Although NSAIDs carry the well-known risk of organ failure and ulcer forma-
tion, NSAIDs at high doses are effective means of pain relief. Corticosteroids, serotonin
inhibitors and norepinephrine inhibitors are all pharmacologic agents that can help allevi-
ate pain.
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Other measures which could be employed to reduce pain, with little to no risk to the patient,
include the use of steroid injections for musculoskeletal pain, physical therapy, massage,
exercise and chiropractic care [34].
3. NSAIDs
NSAIDs are generally considered non-specific analgesic medications and these are commonly
prescribed for inflammation-derived acute pain. This class of drugs acts mainly through the
inhibition COX (cyclooxygenase) synthesis, this then leads to a decreased in the synthesis of
prostaglandin [35]. Being widely diffused, NSAIDs are often used in combination with further
on-going treatments, leading to final effects dependent on drug-drug interactions [1]. How-
ever, prescribers should take into account the intrinsic risk of NSAIDs’ ADRs (Table 2).
Complications involving the gastrointestinal tract as a consequence of NSAID use are com-
mon, especially in combination with the presence of risk factors [36]. NSAIDs exert their effects
through the inhibition of COX and the pharmacological inhibition of COX (both 1 and 2
isoenzymes) works to provide relief from the symptoms of inflammation and pain.
This NSAID-induced decrease in prostaglandin synthesis is responsible for side effects such as
dyspepsia, abdominal pain, nausea, vomiting, heartburn, haemorrhage (NSAIDs could also
lead to prolongation of bleeding time and a significantly increased risk of haemorrhage by
altering vascular homeostasis), ulceration, perforation or obstruction [37].Therefore, COX-2
specific inhibitors, for example celecoxib, have a lower risk of causing gastrointestinal related
ADRs [38].
NSAIDs are also a cause of renal complications. Acute renal failure is a possible consequence
of NSAID use. While this is an intrinsic risk of NSAID medications, it is more likely to occur in
geriatric patients and in patients using enzyme inhibitors (ACEIs) or angiotensin receptor II
blockers [39]. NSAIDs are the class of medicines that are most commonly associated with
hypersensitivity reactions. Because of this, it is generally not recommended to use NSAIDs
even after having an unrelated hypersensitivity reaction or having positive allergy tests.
NSAID-triggered hypersensitivity reactions can result in respiratory complications or in der-
matological problems [40, 41].
1. Gastrointestinal bleeding
2. Cardiovascular disease
3. Stroke
4. Thrombotic disease
5. Arrhythmia
Table 2. The intrinsic risk of ADRs associated with NSAIDs [7, 40].
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Long-term NSAID use is often associated with cardiovascular complications such as strokes
and myocardial infarctions, especially with COX-2 inhibitor therapy. This is an important
factor to consider in patients with pre-existing cardiovascular diseases, where the use of
NSAIDs could potentially worsen their condition, especially in combination with other drug
treatments [42, 43]. Liver toxicity is also commonly associated with NSAID use, in particular
nimesulide, making this medication particularly unsuitable for long-term applications in
patients affected by chronic conditions [44].
Health care providers should also ensure that NSAIDs are prescribed properly and monitored
closely considering the aforementioned ADRs; this can be done by precision treatment of patients.
Physicians should first consider prescribing the lowest effective dose of NSAIDs to those who
have not found alleviation of pain after taking paracetamol. Patients who require NSAIDs
have to be treated according to their gastrointestinal risk profile, because the use of NSAID is
associated with increased ADRs of the entire GI tract, thus increasing mortality. Therefore, a
gastro-protective pharmacologic agent such as misoprostol should be prescribed along with
the NSAID even though it may not completely eradicate the risk of ADRs such as bleeding, the
incidence of ulcer disease will be reduced [45].
Furthermore, physicians should be precise when evaluating patients for NSAID therapy espe-
cially in patients with existing cardiovascular conditions as the use of these medications could
increase the risk of cardiovascular events occurring. Namely, celecoxib carries the highest risk
of coronary artery events at high doses and thus one should consider an alternative like
naproxen in place of its use [45].
4. Acetaminophen
Acetaminophen is often used as the first-line treatment for pain relief for many diagnoses
across the fields of medicine, globally. As an over the counter medication, it is either prescribed
by a doctor or bought by patients. The patients either complete the course as directed or they
continue buying and self-treat with the medication, managing the doses on their own and
subsequently increasing the dose with increasing pain. This behaviour, which is encouraged
by some physicians, can be fatal and has been proven to be useless in most cases of long-term
chronic pain management [46].
It is now known that acetaminophen is not effective in substantially reducing chronic pain
conditions such as osteoarthritis, back pain or post-operative pain [47, 48]. A careful,
systematic and thorough review of acetaminophen use becoming a public health and ethical
concern must be gauged in depth across the globe. When one considers the ADRs associ-
ated with its use, acetaminophen as a first-line treatment for chronic pain seems to call for
further evaluation; ADRs such as liver failure can occur in any patient demographic regard-
less of pre-existing conditions ranging from abnormal liver enzyme profiles to requiring
liver transplantation.
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Of note, hepatotoxicity is considered when more than 4 gm of acetaminophen have been
administered in 1 day [49], but there have been cases of liver injury occurring even at lower
doses [50]; geared with this information, physicians should begin to re-evaluate their stance on
acetaminophen being completely safe for use with patients at home, regardless of their liver
health status and especially in the setting of long-term chronic pain management.
5. Adjuvant therapy
Adjuvant analgesics are defined as drugs with a primary indication other than pain that have
analgesic properties in some painful conditions. The group includes numerous drugs in diverse
classes. Although the widespread use of these drugs as first-line agents, the term “adjuvant” is a
misnomer, they usually are combined with a less-than-satisfactory opioid regimen, in particular
when administered for cancer pain. Some adjuvant analgesics are useful in several painful
conditions and are described as multipurpose adjuvant analgesics (antidepressants, corticoste-
roids, α2-adrenergic agonists, neuroleptics), whereas others are specific for neuropathic pain
(anticonvulsants, local anesthetics, N-methyl-D-aspartate receptor antagonists), bone pain (calci-
tonin, bisphosphonates, radiopharmaceuticals), musculoskeletal pain (muscle relaxants) or pain
from bowel obstruction (octreotide, anticholinergics).
Antidepressants, namely triclyclics (TCAs), which are used as adjuvants for pain management,
can sometimes cause lethal cardiotoxicity as an ADR. In order to reduce the likelihood of this,
the prescribing physician is advised to order an electrocardiogram in those patients with a
history of heart disease, or simply provide a better tolerated alternative, such as desipramine
and nortripltyline. Orthostatic hypertension, acute glaucoma and cognitive impairment are
also ADRs caused by TCAs which can be avoided by screening patients for pre-existing
conditions and previous episodes of these diseases in order to reduce the likelihood of a
reaction [51].
Corticosteroids, although well tolerated at moderated doses, can cause ADRs such as increas-
ing the risk of peptic ulcer disease at a higher prolonged dose. One way to ameliorate this side
effect is by prescribing a gastro-protective formulation, hence reducing the possible damage to
the gastric lining [51].
Medications in the α2-adrenergic drug class (clonidine and tizanidine) are only used as a last
resort adjuvant, due to their serious side effects [51] which include somnolence and hypotension.
Olanzapine, along with other neuroleptics, are also used as an adjuvant only in cases where
the patient is being treated for dementia or agitation. ADRs caused by olanzapine including
tardive dyskinesia and neuroleptic malignant syndrome greatly reduce the quality of life of
patients, which is undesirable [51].
Anticonvulsant drugs are now widely used to treat cancer-related neuropathic pain.
Gabapentin and lamotrigine have both been proven to improve the condition of patients
with neuropathic pain but these also cause side effects such as somnolence, dizziness and
unsteadiness [51].
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Calcitonin, another adjuvant, may cause a hypersensitivity reaction at the onset of administra-
tion when given subcutaneously, this requires skin testing, but has been identified, along with
nausea as a minor side effect when used as an adjuvant in palliative care [51].
Radionuclide pharmaceutical agents have been used to treat metastatic bone disease, namely
strontium and samarium, but using these medications can lead to myelosuppression, a severe
unwanted ADR [51].
Therefore, it can be said that adjuvants also present with their own pertinent adverse drug
reactions that could damper the overall effectiveness in improving the condition of a patient
with long-term use, which does not improve the patient's quality of life.
6. Conclusions
Analgesics are essential pain relievers in modern medicine. However, analgesic misuse and
their adverse effects can affect the efficiency of pain treatment and the eventual outcome could
reduce the quality of life of patients. This review aims to highlight the most common adverse
drug reactions of analgesic treatments and the possible safety risks involved with their use.
Drug-drug interactions can be sometimes responsible for the adverse effects. However, a
significant proportion of analgesic ADRs are preventable, which would reduce the patients’
suffering. Acknowledging potential safety problems represents the first step for health pro-
fessionals in assuring a safe and efficient analgesic treatment with minimum risks to patients.
But being aware of the potential risks of the drugs should not be an impediment for health
professionals to initiate analgesic therapy when necessary.
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